The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study

Infectious Agents and Cancer

Volumn 10, Issue 1, 2015, Pages

  Raffetti, Elena ^a   Donato, Francesco ^a   Castelli, Francesco ^b   Maggiolo, Franco ^c   Carosi, Giampiero ^d   Quiros Roldan, Eugenia ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^d Fondazione Malattie Infettive e Salute Internazionale   (Italy)

Author keywords

Cancer; HIV; Inflammation based biomarkers; NLR; PLR

Indexed keywords

ADULT; ANUS CANCER; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CUTANEOUS MELANOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; PLATELET LYMPHOCYTE RATIO; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECTUM CANCER; RETROSPECTIVE STUDY; SOLID NON AIDS DEFINING CANCER; SOLID TUMOR;

EID: 84946478661     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/s13027-015-0032-y     Document Type: Article

References (26)

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-44.
2. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer. 2008;123(5):1133-40.
3. Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20(1):15-26.
4. Zhou B, Shu B, Yang J, Liu J, Xi T, Xing Y. C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. Cancer Causes Control. 2014;25(10):1397-405.
5. Robbins H, Pfeiffer R, Shiels M, Li J, Hall H, Engels E. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst. 2015;107(4):dju503.
6. Raffetti E, Albini L, Gotti D, Segala D, Maggiolo F, Di Filippo E, et al. Cancer incidence and mortality for all causes in HIV-Infected patients over a Quarter Century: a multicentre cohort study. BMC Public Health. 2015;15:235.
7. Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29(4):463-71.
8. Borges ÁH, O'Connor JL, Phillips AN, Rönsholt FF, Pett S, Vjecha MJ, et al. Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis. 2015;212(4):585-95.
9. Neuhaus J, Jacobs Jr DR, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788-95.
10. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012;55:126-36.
11. McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NC, Melbourne K, et al. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr. 2014;65(2):167-74.
12. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248-59.
13. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.
14. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204-12.
15. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One. 2014;9(6):e101119.
16. Raffetti E, Donato F, Pezzoli C, Digiambenedetto S, Bandera A, Di Pietro M, et al. Systemic inflammation-based biomarkers and survival in HIV-positive subject with solid cancer in an Italian multicenter study. J Acquir Immune Defic Syndr. 2015;69(5):585-92.12.
17. Gotti D, Raffeti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, et al. Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an Italian multicenter study. PLoS One. 2014;9(4):e94768.
18. World Health Organization. International Classification of Disease. http://www.who.int/classifications/icd/en/. Last access March 2015.
19. Breslow NE, Day NE. Rates and rate standardization. In: Breslow NE, Day NE, editors. Statistical methods in cancer research, The design and analysis of cohort studies. IARC scientific publication No. 82, vol. 2. Lyon: International Agency for Research of Cancer; 1987. p. 48-81.
20. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006;24(33):5216-22.
21. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2413-8.
22. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol. 2013;177(1):3-13.
23. Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, et al. C-reactive protein and risk of breast cancer. J Natl Cancer Inst. 2007;99(11):890-4.
24. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med. 2005;142(6):425-32.
25. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291(5):585-90.
26. Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park JH, et al. Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst. 2013;105(24):1871-80.